

Supporting Information

Nanoscale Quality Control Framework for Assessing FFPE DNA Integrity in Cancer Research

Zixuan Huang^{1ab}, Yunpei Si^{1 a}, Yi Zhang^{1 a}, Zicheng Huang^b, Xuehao Xiu^a, Yunshan Wang^c, YuDong Wang^{b*}, Chunhai Fan^d, Ping Song^{ab *}

^a Department of Gynecologic Oncology, The International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University, Shanghai 200240, China.

^b School of Biomedical Engineering, Zhangjiang Institute for Advanced Study and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai 200240, China.

^c Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China

^d State Key Laboratory of Synergistic Chem-Bio Synthesis, School of Chemistry and Chemical Engineering, New Cornerstone Science Laboratory, Frontiers Science Center for Transformative Molecules, Zhangjiang Institute for Advanced Study and National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai 200240, China

*Corresponding authors.

E-mail addresses: songpingsjtu@sjtu.edu.cn (P. Song), wangyudong@shsmu.edu.cn (Y. Wang)

¹ These authors contributed equally to this work.

List of Tables

Table S1. Sequences of different RP for rs206781 amplification.

Table S2. Sequences of different RP for rs2638145 amplification.

Table S3. Sequences of different RP for rs2510152 amplification.

Table S4. List of SNPs used for qPCR multi-amplicon length testing.

Table S5. Sequences of different RP corresponding to various amplicon lengths for SNPs used in qPCR multi-amplicon length testing.

Table S6. Full amplicon sequences (250 bp) for SNPs used in qPCR multi-amplicon length testing.

Table S7. List of SNPs used in NGS.

List of Figures

Fig. S1. qPCR amplification curves for FFPE samples of different years and cell lines at rs206781 with multiple amplicon lengths.

Fig. S2. qPCR amplification curves for FFPE sample S1-2018, and cell lines HEK293-T and NA18562 at locus rs10230708 with multiple amplicon lengths.

Fig. S3. qPCR amplification curves for FFPE sample S1-2018, and cell lines HEK293-T and NA18562 at locus rs2301720 with multiple amplicon lengths.

Fig. S4. qPCR amplification curves for FFPE sample S1-2018, and cell lines HEK293-T and NA18562 at locus rs4712476 with multiple amplicon lengths.

Fig. S5. qPCR amplification curves for samples of different tissue origins: S5-2024 (EC), S7-2024 (HCC), and S8-2024 (HCC) at locus rs206781 with multiple amplicon lengths.

Fig. S6. Chromosomal coverage of FF and FFPE samples after targeted library preparation and NGS.

Fig. S7. Gel electrophoresis results of samples S4-2024 (lane 1), S5-2024 (lane 2), S9-2023 (lane 3), S1-2018 (lane 4), and S10-2019 (lane 5) processed by NovaSeq.

Fig. S8. Quality score distribution of sequencing reads. (a) Quality score distribution of S5-2024 reads. (b) Quality score distribution of S1-2018 reads. The x-axis represents the base position in the reads, and the y-axis represents the quality score per base. The first half shows the quality distribution of the forward reads, while the second half represents the reverse reads.

Fig. S9. WES mutation analysis of samples S5-2024 and S1-2018. (a) Proportional distribution of base substitution types in somatic mutations. (b) Chromosomal distribution pattern of detected mutations.

1. DNA sequences for qPCR amplification

1) rs206781

FP: CACTTCCTCCAGAAGGTCAAAG

Table S1. Sequences of different RP for rs206781 amplification.

RP NO.	RP sequence	Genomic position	Amplicon length (bp)	Amplicon sequence
RP1	TGGCAGTGCTGC TTTAGGC	Chr6:119277 839- 119277829	50	CACTTCCTCCAGAAGGTCCAAA GCCAGAAGGGCCTAAAGCAGCA CTGCCA
RP2	GAAGTCCAAGA AAGCAAGTGGC	Chr6:329782 72-32978381	80	CACTTCCTCCAGAAGGTCCAAA GCCAGAAGGGCCTAAAGCAGCA CTGCCACCCCCACTGCCACTTGC TTTCTTGGACTTC
RP3	GCCTAGGGCACC CCGC	Chr6:329782 72-32978381	110	CACTTCCTCCAGAAGGTCCAAA GCCAGAAGGGCCTAAAGCAGCA CTGCCACCCCCACTGCCACTTGC TTTCTTGGACTTC
RP4	CCGAGCTGGGC CGAT	Chr6:329782 42-32978381	140	CACTTCCTCCAGAAGGTCCAAA GCCAGAAGGGCCTAAAGCAGCA CTGCCACCCCCACTGCCACTTGC TTTCTTGGACTTC
RP5	AGAACCGGAAG GCAGAGAAC	Chr6:329782 14-32978381	168	CACTTCCTCCAGAAGGTCCAAA GCCAGAAGGGCCTAAAGCAGCA CTGCCACCCCCACTGCCACTTGC TTTCTTGGACTTC
RP6	CCCAAGAGGAA AAGAGAGAAAA AAGAG	Chr6:329781 80-32978381	202	CACTTCCTCCAGAAGGTCCAAA GCCAGAAGGGCCTAAAGCAGCA CTGCCACCCCCACTGCCACTTGC TTTCTTGGACTTC

				CTCGGCCTCGATGCTCTCTGCC
				TTCCGTTCTTCTTTCTCTTT
				TTCTCTCTTTCTCTTGGG
				CACTTCCTCCAGAAGGTCCAAA
				GCCAGAAAGGCCTAAAGCAGCA
				CTGCCACCCCCACTGCCACTTGC
				TTTCTTGGACTTCTTAGGTTGAG
				GTGGGCGGGGTGCCCTAGGCC
				CTTGTCACTTCATCGGCCCCAG
				CTCGGCCTCGATGCTCTCTGCC
				TTCCGTTCTTCTTTCTCTTT
				TTCTCTCTTTCTCTTGGGCTTG
				GATATTGGACCCCTGGGACAGAG
				CA
				CACTTCCTCCAGAAGGTCCAAA
				GCCAGAAAGGCCTAAAGCAGCA
				CTGCCACCCCCACTGCCACTTGC
				TTTCTTGGACTTCTTAGGTTGAG
				GTGGGCGGGGTGCCCTAGGCC
				CTTGTCACTTCATCGGCCCCAG
				CTCGGCCTCGATGCTCTCTGCC
				TTCCGTTCTTCTTTCTCTTT
				TTCTCTCTTTCTCTTGGGCTTG
				GATATTGGACCCCTGGGACAGAG
				CAGCCAGTTGTCATGTACTGCC
				CGAAGCTAA

2) rs2638145

FP: GGATGGGACTCCAATGCAAAACT

Table S2. Sequences of different RP for rs2638145 amplification.

RP NO.	RP sequence	Genomic position	Amplicon length (bp)	Amplicon sequence
RP1	CCCTAGACATCC	Chr3:222767	51	GGATGGGACTCCAATGCAAAAC
	TCACACTGATAC	59-22276809		TCAATGTATCAGTGTGAGGATG TCTAGGG
RP2	TTTATTATTTGT	Chr3:222767	82	GGATGGGACTCCAATGCAAAAC
	TCCATTCTATAT	59-22276840		TCAATGTATCAGTGTGAGGATG TCTAGGGTAAGAAATATAGAAT GGAACAAAATAATAAAGGGTAC
RP3	ACAGGAAAAGA	Chr3:222767	109	GGATGGGACTCCAATGCAAAAC
	AACTAAAATTGT	59-22276867		TCAATGTATCAGTGTGAGGATG TCTAGGGTAAGAAATATAGAAT GGAACAAAATAATAAAGGGTAC AATTTAGTTCTTTCTGT
RP4	ATATTATCTATT		142	GGATGGGACTCCAATGCAAAAC
	TTCAGATATAAA	Chr3:222767		TCAATGTATCAGTGTGAGGATG TCTAGGGTAAGAAATATAGAAT GGAACAAAATAATAAAGGGTAC AATTTAGTTCTTTCTGTCT
RP5	AATTTAGAACAG	59-22276900	170	AAAATTTATATCTGAAAATAG ATAATAT
				ATAATAT
RP6	TCTCTGTTATT		202	GGATGGGACTCCAATGCAAAAC
	CTGACAATTAA	Chr3:222767		TCAATGTATCAGTGTGAGGATG TCTAGGGTAAGAAATATAGAAT GGAACAAAATAATAAAGGGTAC AATTTAGTTCTTTCTGTCT
RP6	TTCATATTATCT	59-22276928		AAAATTTATCTGAAAATAG ATAATATGAATAAAATTGTCAG AAATAACAAGAGA
	ATT			
RP6	TCTTAAGTGAAT	Chr3:222767	202	GGATGGGACTCCAATGCAAAAC
	GCATGTGTTGAA	59-22276960		TCAATGTATCAGTGTGAGGATG TCTAGGGTAAGAAATATAGAAT GGAACAAAATAATAAAGGGTAC AATTTAGTTCTTTCTGTCT
RP6	ATAAC			AAAATTTATCTGAAAATAG ATAATATGAATAAAATTGTCAG

				AAATAACAAGAGATTGTTATTT CAACACATGCATTCACTTAAGA
				GGATGGGACTCCAATGCAAAAC TCAATGTATCAGTGTGAGGATG TCTAGGGTAAGAAATATAGAAT GGAACAAAATAATAAAGGGTAC
RP7	TCTTCATTACCA ACCATGTAAAAT AAAGTCT	Chr3:222767 59-22276988	230	AATTTAGTTCTTTCTGTTCT AAAATTTTATATCTGAAAATAG ATAATATGAATAAAATTGTCAG AAATAACAAGAGATTGTTATTT CAACACATGCATTCACTTAAGA CTTATTTACATGGTTGGTAAT GAAGA
RP8	CATTATATAACT ACTGCTTGTGTT TTCTGTTC	Chr3:222767 59-22277018	260	GGATGGGACTCCAATGCAAAAC TCAATGTATCAGTGTGAGGATG TCTAGGGTAAGAAATATAGAAT GGAACAAAATAATAAAGGGTAC AATTAGTTCTTTCTGTTCT AAAATTTTATATCTGAAAATAG ATAATATGAATAAAATTGTCAG AAATAACAAGAGATTGTTATTT CAACACATGCATTCACTTAAGA CTTATTTACATGGTTGGTAAT GAAGAACAGAAAACACAAGCA GTAGTTATATAATG

3) rs2510152

FP: GGATGGGACTCCAATGCACAACT

Table S3. Sequences of different RP for rs2510152 amplification.

RP NO.	RP sequence	Genomic position	Amplicon length (bp)	Amplicon sequence
RP1	AGCTTGTGT	Chr11:119277839 -119277829	50	ACCCAGGTGAGTTTGTTCAC
	CCAGTGAT			ATGATAACCATATCACTGGACA
	ATGGTTAT			CAAGCT
RP2	TGCTGTCA	Chr11:119277839 -119277917	79	ACCCAGGTGAGTTTGTTCAC
	GTTCTATAA			ATGATAACCATATCACTGGACA
	AGAACATATA			CAAGCTTAGTATATTCTTTAT
RP3	CTAAAGC	Chr11:119277839 -119277946	108	AGAACTGACAGCATAATTGAAT
	TAGTCAAT			TCATTGGAACCCATTGACTA
	GGGTTCCA			ACCCAGGTGAGTTTGTTCAC
	ATGAATTC			ATGATAACCATATCACTGGACA
RP4	AATTAT	Chr11:119277839 -119277976	138	CAAGCTTAGTATATTCTTTAT
	TGAAACCA			AGAACTGACAGCATAATTGAAT
	CATACACA			TCATTGGAACCCATTGACTAGA
	CAAATTCA			TTAGTGAATTGTGTATGTG
	CT			GTTTCA
RP5	GGGTCTTA TTTTAAGCT CCAGGG	Chr11:119277839 -119277859	168	ACCCAGGTGAGTTTGTTCAC
				ATGATAACCATATCACTGGACA
				CAAGCTTAGTATATTCTTTAT
				AGAACTGACAGCATAATTGAAT
				TCATTGGAACCCATTGACTAGA
RP6	TTTATTTT TATTAAAC CAGAAAGC ATCTAGTCT G	Chr11:119277839 -119278040	202	TTAGTGAATTGTGTATGTG
				GTTTCACTTAAACCCCTGGAGC
				TTAAAATAGGACCCAGACTAG
				ATGCTTCTGGTTAATAAAAAA

				ATAAA
				ACCCAGGTGAGTTTGTTCAC ATGATAACCATATCACTGGACA CAAGCTTAGTATATTCTTTAT AGAACTGACAGCATAATTGAAT TCATTGAAACCCATTGACTAGA TTAGTGAATTGTGTATGTG GTTCACTTAAACCCTGGAGC TTAAAATAGGACCCAGACTAG ATGCTTCTGGTTAATAAAAAA ATAAACCACTGTTGTGACATT TTATATAAGCA
RP7	TGCTTATAT AAAAATGT CACAAACAG TGTT	Chr11:119277839 -119278068	230	
RP8	AAAGTGAA GACTTGTTC CCTATACA AATTTG	Chr11:119277839 -119278098	260	

Table S4. List of SNPs used for qPCR multi-amplicon length testing.

SNP	Position (GRCh38)	FP sequence
rs206781	chr6:32978356	GTCTCTGCTTCCTACTCTAACTCAC
rs10230708	chr7:26625472	ACCAATGGGAGTCACTGCTG
rs2301720	chr7:27156450	GTAGCCGCTTCTCTGTGAGTT
rs4712476	chr6:20291800	CCCCGGATGTCAGGGAATG

Table S5. Sequences of different RP corresponding to various amplicon lengths for SNPs used in qPCR multi-amplicon length testing.

SNP	RP Sequence(50bp)	RP Sequence (150bp)	RP Sequence (250bp)
rs206781	GACCTTCTGGAGGAAGT GGC	GGGTCCAATATCCA AGCCA	GGGTCCAATATCCAAG CCCA
rs10230708	GTCCTAACACCTCTTATC ACAGGG	GTGTCAAGTCAGGT ACCCTGAC	GCCATTAACTTAGAA ACTAGCAGAATTAA
rs2301720	GCCGAGCCGACTTCTTG C	CTGCCGGACAACAA ATCACAG	GCTGCAGCGAGCTCC
rs4712476	TTGTGAGACGGGAACAG TGTT	ACCCTTCCGGTGTG GGC	GTACTGAAGAAAAGCA GATCTTAATTGG

Table S6. Full amplicon sequences (250 bp) for SNPs used in qPCR multi-amplicon length testing.

SNP	Amplicon sequence (250bp)
rs206781	CTAGTCTCTGCTTCCTACTCTAACTCACTGGTGCCACTCCTCCAGAAG GTCCAAAGCCaGAAGGGCTAAAGCAGCACTGCCACCCCCACTGCCACT TGCTTCTTGGACTTCTTAGGTTGAGGTGGCGGGGTGCCCTAGGCCCC TTGTCATCTTCATCGGCCAGCTCGGCCTCGATGCTCTGCCTTCCG TTTCTTCTTTCTCTTTCTCTTTCTCTTCCCTTGGCTGGATATTGGA CCCTGGGA
rs10230708	ACCAATGGGAGTCACTGCTGAGGCGCCCTGTGATAAGAGGTGTTAGG ACTCATACTGCCAGATGAGGACACTGATGTCAGGGAGGTAGAGCAG CGTGCCCAAACCCACTCCCTACCATGGGAGGTGTCAGGGTACCTGACTT GACACCCCCAGTTCTTCCACTTAACCCCACAACCTTAAGCCAGCCTGCTCT GCAGTTAGTTAAATTGGCCATTCTTAAATTCTGCTAGTTCTAAGTAAA ATGGCAAGGTATCCATGCCCTTC
rs2301720	GTAGCCGCTTCTGTGAGTTGGAGCAAAGGAGCAAGAAGTCGGCTC GGCATTTGGAACAGAGAACGCCCCCGCGTATATTGCTAAAAAGCGCG TTCACATAATACGAAGAACTCATAATTGACTGTGATTGTTGTCCGG CAGCTTCAGTGTGGTTTACGAGGTAGAGTGATATATGATAACATTA CACCCCCAGATTACACCAAACCCATTTCCTTGGACGGAGCTGCC GCAGCACGTGACCGCCCACATGACCGCCTC
rs4712476	CCCCGGATGTCAGGGAAATGCTCTGTACAAAACACTGTTCCCGTCTCACA AAGCATCTTGAAGATGGAGACGTGCATACTCACAGTTACCACAAAGAG GGCGGTCATAAAAGGGAAAGGTACCCCTGCCCTAAGCCCACACCGGA AGGGTGAATCCATTTAAGGAGGTTGAAGGTATTTTATAATCATGGG CTGCTCCTGGAATTGATAAAACACGATCCAAATTAAGATCTGCTTTCTT CAGTACTATTATGTTAATCCCATT

Table S7. List of SNPs used in NGS.

SNP	Position (GRCh38)	FP sequence	RP sequence
rs10230708	chr7:26625472	ACCAATGGGAGTCACT GCTG	TAAGTGGAAAGAACTG GGGTGTC
rs10104396	chr8:23839899	GAGGGTATTAGAAG AATGACTATGTGA	ACATGGTTAGATATTA GCCTGACCTATG
rs199032	chr6:23438217	GCTCTCCTCTCACAT CTTTATTAAACC	GCAGCCAAGTGTGAAA GTATTGA
rs926850	chr6:24898851	CAGAGTAAAATTACT GCTCCGTCTAA	TGATGTTGAGTTGAGA CAGGTTACA
rs17149369	chr7:24372574	GGATTCCCTAACGCTCT TCAATATTGC	AAATGTAGTTCTATTAT GGTCAGCACAC
rs869720	chr1:38326229	CCTCATCTGTAAAGCA GGGAGAGA	AGTATCCCCAAAAGGT TGCAGAT
rs12478327	chr2:20174488	ACTTCTGCCAACATTC AAATTCAAGG	GTGCAAGCTGGAGGCA CT
rs2638145	chr3:22276782	GGATGGGACTCCAATG CAAAACT	ACAGGAAAAGAAACTA AAATTGTACCCCTT
rs2170091	chr3:22088347	CATCTGCTCTTCATA GATAGCTTCAGA	GAAGCCAGATCTCAA GTGTCCT
rs2043583	chr3:24598078	CCTGAATGTCAGTTT GTTAGAGCAAC	GTTATTGGGAATGCTAT GAAAGAGACA
rs955456	chr4:23651593	CAGACTTAATCAAAGC CCTTGAAAAGA	AGAACTCATTCCCTTAT AGCTGAAGAACT
rs966516	chr4:24775000	CCTCCCATAGTGATT TTATGAAGTCA	GCAGACACTTAGGATG TTTCCAGT
rs354169	chr1:49189758	AATGCTTGCTTGCTG AGAACTT	GAGCCTTAGTTCCCTCCA TCAGTAAA
rs1898170	chr4:29349716	AATGGGAAAACACATT TTAAGGGCA	AAATTACGTTGGTAAT TGGGTCTTGT
rs11247921	chr1:26339111	CCACACTCTGCCTCTC ATGGTAT	CACAGAGGTGACAGAA CACAGT
rs1635718	chr1:35508868	ACTTAAGAGGTCAACA CAGATGAAAATTATC	TAGTTATTACATGGTGGG AAGGCAA
rs10510620	chr3:29288795	TCCGCAAAACCTACAA TCTCTGAA	AAAAGATAATGTTCTT GTTTATATGCCCTTG
rs7104025	chr11:21126827	TCAGATGCTTAGGCT CATGAGTTA	TACAGCAACTCACAAA CTAATGACTCT
rs2246745	chr2:29717663	CTCCTTCCAATCACCA ACAAACAT	GGCTGCGATGAGACAG GAA
rs3789806	chr7:140749271	CTTGTATATAGACGGT AAAATAAACACCAAG	AGGCACCCAGAAAGTCAT CAGAATG

A			
rs706714	chr5:68227023	TGAAGCAGATGTTGAA CAACAAGG	GACCAAGCTTTATGCA CCACA
rs1884444	chr1:67168129	TTCCTGCTTCCAGACA TGAATCA	TGAAAGATAGCAATAG ATACATAAAACACCA
rs2510152	chr11:119277863	ACCCAGGTGAGTTTG TTTCACAT	TGAAACCACATACACA CAAATTCACT
rs16754	chr11:32396399	CTCTCTGCCTGCAGGA TGTG	CTTCCTGCTGTGCATCT GTAAGT
rs206781	chr6:32978356	CACTTCCTCCAGAAGG TCCAAAG	AAAAAGAAGAACGGA AGGCAGAG
rs28932178	chr5:177210575	ACTAAGAGTGCAGAG CCTGGAA	TGCTGCCCAACCTTA TTAAC




Fig. S1. qPCR amplification curves for FFPE samples of different years and cell lines at rs206781 with multiple amplicon lengths.




Fig. S2. qPCR amplification curves for FFPE sample S1-2018, and cell lines HEK293-T and NA18562 at locus rs10230708 with multiple amplicon lengths.




Fig. S3. qPCR amplification curves for FFPE sample S1-2018, and cell lines HEK293-T and NA18562 at locus rs2301720 with multiple amplicon lengths.




Fig. S4. qPCR amplification curves for FFPE sample S1-2018, and cell lines HEK293-T and NA18562 at locus rs4712476 with multiple amplicon lengths.




Fig. S5. qPCR amplification curves for samples of different tissue origins: S5-2024 (EC), S7-2024 (HCC), and S8-2024 (HCC) at locus rs206781 with multiple amplicon lengths.




Fig. S6. Chromosomal coverage of FF and FFPE samples after targeted library preparation and NGS.




Fig. S7. Gel electrophoresis results of samples S4-2024 (lane 1), S5-2024 (lane 2), S9-2023 (lane 3), S1-2018 (lane 4), and S10-2019 (lane 5) processed by NovaSeq.




Fig. S8. Quality score distribution of sequencing reads. (a) Quality score distribution of S5-2024 reads. (b) Quality score distribution of S1-2018 reads. The x-axis represents the base position in the reads, and the y-axis represents the quality score per base. The first half shows the quality distribution of the forward reads, while the second half represents the reverse reads.




Fig. S9. WES mutation analysis of samples S5-2024 and S1-2018.(a) Proportional distribution of base substitution types in somatic mutations. (b) Chromosomal distribution pattern of detected mutations.